Abstract
Extensively drug-resistant (XDR) strains of Mycobacterium tuberculosis, now known to be present in 50 countries, heighten the threat posed by untreatable and fatal human tuberculosis (TB). To combat epidemics of drug-resistant TB, it is vital to understand why some resistant strains have greater reproductive fitness — a greater propensity to spread — than drug-susceptible strains. If public health malpractice has been a more important determinant of reproductive success than genetic mechanisms, then improved diagnosis and treatment could keep the frequency of resistant strains among TB cases low in any population. Recent data suggest that national TB control programmes that use existing drugs efficiently can postpone and even reverse epidemics of multidrug-resistant TB, although the effect of such programmes on XDR strains remains largely unknown.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Raviglione, M. C. & Uplekar, M. W. WHO's new stop TB strategy. Lancet 367, 952–955 (2006).
World Health Organization. Anti-tuberculosis drug resistance in the world: report no. 3 (WHO, Geneva, 2004).
Singh, J. A., Upshur, R. & Padayatchi, N. XDR-TB in South Africa: no time for denial or complacency. PLoS Med. 4, e50 (2007).
Koenig, R. Drug-resistant tuberculosis. In South Africa, XDR TB and HIV prove a deadly combination. Science 319, 894–897 (2008).
Jones, K. D., Hesketh, T. & Yudkin, J. Extensively drug-resistant tuberculosis in sub-Saharan Africa: an emerging public-health concern. Trans. R. Soc. Trop. Med. Hyg. 102, 219–224 (2008).
World Health Organization. Anti-tuberculosis drug resistance in the world: report no. 4 (WHO, Geneva, 2008).
von Gottberg, A. et al. Emergence of levofloxacin-non-susceptible Streptococcus pneumoniae and treatment for multidrug-resistant tuberculosis in children in South Africa: a cohort observational surveillance study. Lancet 371, 1108–1113 (2008).
Hancock, R. E. W. The end of an era? Nature Rev. Drug Discov. 6, 28 (2007).
Raviglione, M. XDR-TB: entering the post-antibiotic era? Int. J. Tuberc. Lung Dis. 10, 1185–1187 (2006).
Norrby, S. R., Nord, C. E. & Finch, R. Lack of development of new antimicrobial drugs: a potential serious threat to public health. Lancet Infect. Dis. 5, 115–119 (2005).
Levy, S. B. & Marshall, B. Antibacterial resistance worldwide: causes, challenges and responses. Nature Med. 10, S122–S129 (2004).
Spigelman, M. K. New tuberculosis therapeutics: a growing pipeline. J. Infect. Dis. 196 (Suppl. 1), 28–34 (2007).
Glickman, S. W., Rasiel, E. B., Hamilton, C. D., Kubataev, A. & Schulman, K. A. A portfolio model of drug development for tuberculosis. Science 311, 1246–1247 (2006).
Dye, C. & Espinal, M. A. Will tuberculosis become resistant to all antibiotics? Proc. R. Soc. Lond. B 268, 45–52 (2001).
World Health Organization. The global MDR-TB and XDR-TB response plan 2007–2008 (WHO, Geneva, 2007).
Dye, C., Espinal, M. A., Watt, C. J., Mbiaga, C. & Williams, B. G. Worldwide incidence of multidrug-resistant tuberculosis. J. Infect. Dis. 185, 1197–1202 (2002).
Zignol, M. et al. Global incidence of multidrug-resistant tuberculosis. J. Infect. Dis. 194, 479–485 (2006).
Cohen, T. et al. Challenges in estimating the total burden of drug-resistant tuberculosis. Am. J. Respir. Crit. Care Med. 177, 1302–1306 (2008).
Ben Amor, Y., Nemser, B., Singh, A., Sankin, A. & Schluger, N. Underreported threat of multidrug-resistant tuberculosis in Africa. Emerg. Infect. Dis. 14, 1345–1352 (2008).
Shah, N. S. et al. Worldwide emergence of extensively drug-resistant tuberculosis. Emerg. Infect. Dis. 13, 380–387 (2007).
Pillay, M. & Sturm, A. W. Evolution of the extensively drug-resistant F15/LAM4/KZN strain of Mycobacterium tuberculosis in KwaZulu-Natal, South Africa. Clin. Infect. Dis. 45, 1409–1414 (2007).
Gandhi, N. R. et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 368, 1575–1580 (2006).
Dye, C. & Espinal, M. A. Will tuberculosis become resistant to all antibiotics? Proc. R. Soc. Lond. B 268, 45–52 (2001).
Dye, C. & Williams, B. G. Criteria for the control of drug-resistant tuberculosis. Proc. Natl Acad. Sci. USA 97, 8180–8185 (2000).
Dye, C., Williams, B. G., Espinal, M. A. & Raviglione, M. C. Erasing the world's slow stain: strategies to beat multidrug-resistant tuberculosis. Science 295, 2042–2046 (2002).
Cohen, T., Sommers, B. & Murray, M. The effect of drug resistance on the fitness of Mycobacterium tuberculosis. Lancet Infect. Dis. 3, 13–21 (2003).
Martinez, J. L., Baquero, F. & Andersson, D. I. Predicting antibiotic resistance. Nature Rev. Microbiol. 5, 958–965 (2007).
Rosas-Magallanes, V. et al. Horizontal transfer of a virulence operon to the ancestor of Mycobacterium tuberculosis. Mol. Biol. Evol. 23, 1129–1135 (2006).
Coros, A., DeConno, E. & Derbyshire, K. M. IS6110, a Mycobacterium tuberculosis complex-specific insertion sequence, is also present in the genome of Mycobacterium smegmatis, suggestive of lateral gene transfer among mycobacterial species. J. Bacteriol. 190, 3408–3410 (2008).
Becq, J. et al. Contribution of horizontally acquired genomic islands to the evolution of the tubercle bacilli. Mol. Biol. Evol. 24, 1861–1871 (2007).
Hazbon, M. H. et al. Population genetics study of isoniazid resistance mutations and evolution of multidrug-resistant Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 50, 2640–2649 (2006).
Prammananan, T. et al. Distribution of rpoB mutations among multidrug-resistant Mycobacterium tuberculosis (MDRTB) strains from Thailand and development of a rapid method for mutation detection. Clin. Microbiol. Infect. 14, 446–453 (2008).
Caws, M. et al. The influence of host and bacterial genotype on the development of disseminated disease with Mycobacterium tuberculosis. PLoS Pathog. 4, e1000034 (2008).
Espinal, M. A. et al. Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countries. J. Am. Med. Assoc. 283, 2537–2545 (2000).
Mak, A. et al. Influence of multidrug resistance on tuberculosis treatment outcomes with standardized regimens. Am. J. Respir. Crit. Care Med. 178, 306–312 (2008).
Cox, H. et al. Tuberculosis recurrence and mortality after successful treatment: impact of drug resistance. PLoS Med. 3, e384 (2006).
Cox, H. S. et al. Risk of acquired drug resistance during short-course directly observed treatment of tuberculosis in an area with high levels of drug resistance. Clin. Infect. Dis. 44, 1421–1427 (2007).
Nathanson, E. et al. Multidrug-resistant tuberculosis management in resource-limited settings. Emerg. Infect. Dis. 12, 1389–1397 (2006).
Leimane, V. et al. Clinical outcome of individualized treatment of multidrug-resistant tuberculosis in Latvia: a retrospective cohort study. Lancet 365, 318–326 (2005).
Furin, J. The clinical management of drug-resistant tuberculosis. Curr. Opin. Pulm. Med. 13, 212–217 (2007).
Shin, S. S. et al. Long-term follow-up for multidrug-resistant tuberculosis. Emerg. Infect. Dis. 12, 687–688 (2006).
Keshavjee, S. et al. Treatment of extensively drug-resistant tuberculosis in Tomsk, Russia: a retrospective cohort study. Lancet 372, 1403–1409 (2008).
Mitnick, C. S. et al. Comprehensive treatment of extensively drug-resistant tuberculosis. N. Engl. J. Med. 359, 563–574 (2008).
World Health Organization. Global tuberculosis control 2008: surveillance, planning, financing (WHO, Geneva, 2008).
World Health Organization. Green Light Committee Initiative. Annual report (WHO, Geneva, 2007).
Kwon, Y. S. et al. Treatment outcomes for HIV-uninfected patients with multidrug-resistant and extensively drug-resistant tuberculosis. Clin. Infect. Dis. 47, 496–502 (2008).
Bonilla, C. A. et al. Management of extensively drug-resistant tuberculosis in Peru: cure is possible. PLoS One 3, e2957 (2008).
Cox, H. S., Morrow, M. & Deutschmann, P. W. Long term efficacy of DOTS regimens for tuberculosis: systematic review. Br. Med. J. 336, 484–487 (2008).
Chan, E. D., Strand, M. J. & Iseman, M. D. Treatment outcomes in extensively resistant tuberculosis. N. Engl. J. Med. 359, 657–659 (2008).
Mariam, D. H., Mengistu, Y., Hoffner, S. E. & Andersson, D. I. Effect of rpoB mutations conferring rifampin resistance on fitness of Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 48, 1289–1294 (2004).
Gagneux, S. et al. The competitive cost of antibiotic resistance in Mycobacterium tuberculosis. Science 312, 1944–1946 (2006).
Strauss, O. J. et al. Spread of a low-fitness drug-resistant Mycobacterium tuberculosis strain in a setting of high human immunodeficiency virus prevalence. J. Clin. Microbiol. 46, 1514–1516 (2008).
European Concerted Action on New Generation Genetic Markers and Techniques for the Epidemiology and Control of Tuberculosis. Beijing/W genotype Mycobacterium tuberculosis and drug resistance. Emerg. Infect. Dis. 12, 736–743 (2006).
Sun, Y. J. et al. Genotype and phenotype relationships and transmission analysis of drug-resistant tuberculosis in Singapore. Intern. J. Tuberc. Lung Dis. 11, 436–442 (2007).
Cox, H. S. et al. The Beijing genotype and drug resistant tuberculosis in the Aral Sea region of Central Asia. Respir. Res. 6, 134 (2005).
Marais, B. J. et al. Beijing and Haarlem genotypes are overrepresented among children with drug-resistant tuberculosis in the Western Cape Province of South Africa. J. Clin. Microbiol. 44, 3539–3543 (2006).
Lopez, B. et al. A marked difference in pathogenesis and immune response induced by different Mycobacterium tuberculosis genotypes. Clin. Exper. Immunol. 133, 30–37 (2003).
Toungoussova, O. S., Caugant, D. A., Sandven, P., Mariandyshev, A. O. & Bjune, G. Impact of drug resistance on fitness of Mycobacterium tuberculosis strains of the W-Beijing genotype. FEMS Immunol. Med. Microbiol. 42, 281–290 (2004).
Blower, S. & Supervie, V. Predicting the future of XDR tuberculosis. Lancet Infect. Dis. 7, 443 (2007).
Cohen, T. & Murray, M. Modeling epidemics of multidrug-resistant M. tuberculosis of heterogeneous fitness. Nature Med. 10, 1117–1121 (2004).
Blower, S. M. & Chou, T. Modeling the emergence of the 'hot zones': tuberculosis and the amplification dynamics of drug resistance. Nature Med. 10, 1111–1116 (2004).
DeRiemer, K. et al. Does DOTS work in populations with drug-resistant tuberculosis? Lancet 365, 1239–1245 (2005).
Espinal, M. A. & Dye, C. Can DOTS control multidrug-resistant tuberculosis? Lancet 365, 1206–1209 (2005).
Wu, P. et al. Age-period-cohort analysis of tuberculosis notifications in Hong Kong from 1961 to 2005. Thorax 63, 312–316 (2008).
Dye, C. in Clinical Tuberculosis 4th edn (eds Davies, P. D. O., Barnes, P. F. & Gordon, S. B.) 21–41 (Hodder Arnold, London, 2008).
Dye, C., Garnett, G. P., Sleeman, K. & Williams, B. G. Prospects for worldwide tuberculosis control under the WHO DOTS strategy. Directly observed short-course therapy. Lancet 352, 1886–1891 (1998).
Styblo, K. & Bumgarner, J. R. Tuberculosis can be controlled with existing technologies: evidence. Tubercul. Surveill. Res. Unit. Progress Report 2, 60–72 (1991).
Nardell, E. A. Environmental infection control of tuberculosis. Semin. Respir. Infect. 18, 307–319 (2003).
Bock, N. N., Jensen, P. A., Miller, B. & Nardell, E. Tuberculosis infection control in resource-limited settings in the era of expanding HIV care and treatment. J. Infect. Dis. 196 (Suppl. 1), 108–113 (2007).
World Health Organization. Tuberculosis infection control in the era of expanding care and treatment (WHO, Geneva, 2007).
World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis (WHO, Geneva, 2006).
Cobelens, F. G. et al. Scaling up programmatic management of drug-resistant tuberculosis: a prioritized research agenda. PLoS Med. 5, e150 (2008).
Mitnick, C. D., Appleton, S. C. & Shin, S. S. Epidemiology and treatment of multidrug resistant tuberculosis. Semin. Respir. Crit. Care Med. 29, 499–524 (2008).
Nunn, A. J., Phillips, P. P. & Gillespie, S. H. Design issues in pivotal drug trials for drug sensitive tuberculosis (TB). Tuberculosis (Edinb.) 88 (Suppl. 1), 85–92 (2008).
Borgdorff, M. W., Floyd, K. & Broekmans, J. F. Interventions to reduce tuberculosis mortality and transmission in low- and middle-income countries. Bull. World Health Organ. 80, 217–227 (2002).
Styblo, K. Epidemiology of Tuberculosis (KNCV Tuberculosis Foundation, The Hague, 1991).
China Tuberculosis Control Collaboration. The effect of tuberculosis control in China. Lancet 364, 417–422 (2004).
Dye, C., Ottmani, S., Laasri, L. & Bencheikh, N. The decline of tuberculosis epidemics under chemotherapy: a case study in Morocco. Int. J. Tuberc. Lung Dis. 11, 1225–1231 (2007).
Suarez, P. G. et al. The dynamics of tuberculosis in response to 10 years of intensive control effort in Peru. J. Infect. Dis. 184, 473–478 (2001).
Acknowledgements
I thank A. Wright and M. Zignol for providing data from the 2008 WHO/IUATLD report on drug resistance and for helpful discussions about data interpretation. I also thank T. Cohen and M. Raviglione for reviewing drafts of the manuscript.
Author information
Authors and Affiliations
Related links
Related links
DATABASES
Entrez Genome Project
FURTHER INFORMATION
Rights and permissions
About this article
Cite this article
Dye, C. Doomsday postponed? Preventing and reversing epidemics of drug-resistant tuberculosis. Nat Rev Microbiol 7, 81–87 (2009). https://doi.org/10.1038/nrmicro2048
Issue Date:
DOI: https://doi.org/10.1038/nrmicro2048
This article is cited by
-
Antimycobacterial, antibiofilm and efflux pump inhibitory activity of extracts from selected Combretum species used in traditional medicine in Zimbabwe
Advances in Traditional Medicine (2023)
-
Integrity of the Actin Cytoskeleton of Host Macrophages is Necessary for Mycobacterial Entry
The Journal of Membrane Biology (2022)
-
Prisons as ecological drivers of fitness-compensated multidrug-resistant Mycobacterium tuberculosis
Nature Medicine (2021)
-
Does higher education prepare students to bridge divides in today’s democracy?
Journal of Environmental Studies and Sciences (2020)
-
Models of immune selection for multi-locus antigenic diversity of pathogens
Nature Reviews Immunology (2019)